http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2614728-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_586f93fcd79a7a9b358f117970d4f8e3 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
filingDate | 2012-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cee931b6f41d0a4fec68a21af8ba011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04ccf3729cc70a33b766cc466cb1fe7c |
publicationDate | 2017-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2614728-C2 |
titleOfInvention | Pharmaceutical composition for oral administration containing statin |
abstract | FIELD: pharmaceutics. n SUBSTANCE: invention relates to pharmaceutical composition for oral administration containing or consisting of: (i) from 11 to 25 wt% of simvastatin, (ii) from 0.01 to 3 % by weight of first substance (A1) with antioxidant activity, which is butylhydroxyanisole, (iii) from 0.01 to 3 % by weight of second substance (A2) with antioxidant activity, differing from first substance (A1) with antioxidant activity, which is citric acid, and (iv) from 75 to 85 wt% of at least one additive selected from group consisting of filler, binder, agents for controlling fluidity, baking powder and agent preventing adhesion or combinations thereof, where quantitative ratio of butylhydroxyanisole (A1) and citric acid (A2) ranges from 1:95 to 1:30, and wherein above composition is compacted in form of tablet and said tablet has mass from 130 to 300 mg. n EFFECT: invention also relates to use of said pharmaceutical composition in medicine. n 12 cl, 2 ex, 4 tbl, 5 dwg |
priorityDate | 2011-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.